找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Applications of Pharmacokinetic Principles in Drug Development; Rajesh Krishna Textbook 2004 Kluwer Academic/Plenum Publishers, New York 2

[復(fù)制鏈接]
樓主: affront
51#
發(fā)表于 2025-3-30 08:23:22 | 只看該作者
Food-Drug Interactions: Drug Development Considerations,trates a direct pharmacological interaction in which a meal component alters clinical response to oral drug administration dictating marketed product insert warnings and special prescription labeling.
52#
發(fā)表于 2025-3-30 14:43:10 | 只看該作者
Drug-Drug Interactions,s in drug exposure and to clinically significant QT prolongation or, in some cases, serious arrhythmias. Mibefradil, also a CYP3A4 substrate, is a potent inhibitor of CYP3A4 and P-gp transporter. Concomitant administration of mibefradil with other CYP3A4 and P-gp substrates can lead to increased adv
53#
發(fā)表于 2025-3-30 19:45:04 | 只看該作者
Role of Preclinical Metabolism and Pharmacokinetics in The Development of Celecoxib,s that target COX-2 relative to COX-1.brought into clinical use new drugs that obviated the toxicological limitations of older NSAIDs. Celecoxib (Celebrex.), the first drug approved based on this COX-2 selectivity, entered clinical use in 1999. In the context of this chapter, COX-2-selective refers
54#
發(fā)表于 2025-3-31 00:40:13 | 只看該作者
Efficient and Effective Drug Development,that is changing every day. Research commitments are complicated by a limited but growing understanding of disease processes as well as the spread of new afflictions such as AIDS, West Nile Fever, etc. to larger and larger populations. In addition, improved medical treatments of disease have resulte
55#
發(fā)表于 2025-3-31 02:20:47 | 只看該作者
Bioanalytical Methods: Challenges and Opportunities in Drug Development,es has been evolving for decades. The uninterrupted introduction of new technologies and the increasing attention being paid by global regulatory authorities to validation issues has continued to shape this scientific field. However, in the last five years, there has been an unprecedented increase b
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 21:49
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
禹州市| 沾益县| 大同市| 应城市| 资中县| 张家口市| 洛宁县| 奈曼旗| 五莲县| 威远县| 临高县| 乃东县| 洛南县| 海原县| 城固县| 巢湖市| 大田县| 庄河市| 含山县| 天祝| 凌源市| 屯留县| 衢州市| 广灵县| 定西市| 安平县| 吴旗县| 万山特区| 靖江市| 佛山市| 沧源| 开封市| 奉节县| 平原县| 米泉市| 连江县| 永春县| 田林县| 个旧市| 贞丰县| 溧水县|